Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors
April 06 2021 - 8:00AM
Business Wire
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the
“Company” or “Second Sight”), a leading developer and marketer of
implantable visual prosthetics that are intended to create an
artificial form of useful vision for blind individuals, today
announced that the Company’s Board of Directors has appointed two
new members, Dr. Dean Baker and Ms. Alexandra Larson. Dr. Baker has
also been appointed to the Audit Committee of the Board.
“We are honored and excited to add these two very talented
individuals to our board,” said Gregg Williams, Chairman of the
Board. “I have worked with both for many years and know they are
the exact blend of talent and experience we need to move this
company strongly forward in our mission to cure all forms of
blindness,” concluded Williams.
Dean Baker, Ph.D.
Dr. Baker serves on the Board of Directors of Nano Precision
Medical and served on the Board of Directors of Advanced Bionics
prior to its sale to Boston Scientific. In addition, he was the
founding director of the Alfred E. Mann Institute for Biomedical
Engineering at USC, and served for nine years on the Board of
Directors (including serving on compensation, audit, and governance
committees) for Semtech, a publicly traded semiconductor company.
He currently serves on the Board of Directors for Transonic
Imaging, a medical imaging startup. Dr. Baker was also a vice
president of Northrop Grumman for 16 years including overseeing a
division with $1 billion in annual sales.
Alexandra Larson, JD, MBA
Ms. Larson is Vice President and General Counsel of Williams
International, a privately-held designer and manufacturer in the
aerospace and defense industry. Prior to Williams International,
Ms. Larson was Legal Director and Associate General Counsel at
Amcor, Corporate Counsel at Compuware Corporation, and an associate
at Baker and McKenzie. Ms. Larson has also held positions with the
New York Stock Exchange and United States Department of Justice,
Antitrust Division.
On April 5, 2021 Nasdaq notified the Company that it was not in
compliance with the audit committee composition requirement and
thus may be subject to delisting. The Company believes the addition
of Mr. Baker to the audit committee puts it back into compliance
with Nasdaq rules regarding audit committee composition. Nasdaq
further notified the Company on April 5, 2021, that due to Matt
Pfeffer’s resignation as Acting CEO within one year of his
appointment, staff has determined that Mr. Pfeffer is independent
and that the Company was in compliance with rules regarding
director independence.
About Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. (Nasdaq: EYES) develops and
markets implantable visual prosthetics that are intended to deliver
useful artificial vision to blind individuals. A recognized global
leader in neuromodulation devices for blindness, the Company is
committed to developing new technologies to treat the broadest
population of sight-impaired individuals. The Company’s
headquarters are in Los Angeles, California. More information is
available at https://secondsight.com.
Safe Harbor
This press release contains certain “forward-looking statements”
within the meaning of the “safe harbor” provisions of the US
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “target,” “believe,”
“expect,” “will,” “may,” “anticipate,” “estimate,” “would,”
“positioned,” “future,” and other similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. Examples of forward-looking statements include,
among others, statements made in this press release regarding the
use of proceeds from the private placement. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on Second Sight’s current
beliefs, expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control.
Actual results and outcomes may differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important
factors that could cause actual results and outcomes to differ
materially from those indicated in the forward-looking statements
include, among others, the following: (1) legal claims or
proceedings relating to Second Sight’s termination of the
Memorandum of Understanding with Pixium Vision and costs relating
thereto; (2) changes in applicable laws or regulations; (3) the
possibility that Second Sight may be adversely affected by other
economic, business, and/or competitive factors; (4) the impact of
COVID-19 on Second Sight’s business; and (5) other risks and
uncertainties indicated from time to time in Second Sight’s Form
10-K for the year ended December 31, 2020, including those under
“Risk Factors” therein, and in Second Sight’s other filings with
the SEC. Some of these risks and uncertainties may in the future be
amplified by the COVID-19 outbreak and there may be additional
risks that Second Sight considers immaterial or which are unknown.
A further list and description of risks and uncertainties can be
found in Second Sight’s Annual Report on Form 10-K, filed on March
16, 2021. Any forward-looking statement made by us in this press
release is based only on information currently available to Second
Sight and speaks only as of the date on which it is made. Second
Sight undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210406005404/en/
Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793 E: lwilson@insitecony.com
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Aug 2024 to Sep 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Sep 2023 to Sep 2024